Microtubules
play a crucial role in maintenance of structure, function, axonal
extensions, cargo transport, and polarity of neurons. During neurodegenerative
diseases, microtubule structure and function get severely damaged
due to destabilization of its major structural proteins. Therefore,
design and development of molecules that stabilize these microtubule
networks have always been an important strategy for development of
potential neurotherapeutic candidates. Toward this venture, we designed
and developed a tyrosine rich trisubstituted triazine molecule (TY3)
that stabilizes microtubules through close interaction with the taxol
binding site. Detailed structural investigations revealed that the
phenolic protons are the key interacting partners of tubulin. Interestingly,
we found that this molecule is noncytotoxic in PC12 derived neurons,
stabilizes microtubules against nocodazole induced depolymerization,
and increases expression of acetylated tubulin (Ac-K40), an important
marker of tubulin stability. Further, results show that TY3 significantly
induces neurite sprouting as compared to the untreated control as
well as the two other analogues (TS3 and TF3). It also possesses anti-Aβ
fibrillation properties as confirmed by ThT assay, which leads to
its neuroprotective effect against amyloidogenic induced toxicity
caused through nerve growth factor (NGF) deprivation in PC12 derived
neurons. Remarkably, our results reveal that it reduces the expression
of TrkA (pY490) associated with NGF deprived amyloidogenesis, which
further proves that it is a potent amyloid β inhibitor. Moreover,
it promoted the health of the rat primary cortical neurons through
higher expression of key neuronal markers such as MAP2 and Tuj1. Finally,
we observed that it has good serum stability and has the ability to
cross the blood–brain barrier (BBB). Overall, our work indicates
the importance of phenolic −OH in promoting neuroprotection
and its importance could be implemented in the development of future
neurotherapeutics.